Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964856 | 0.91 | MEN1 (0.40) | KDM4ECNR2CNR1MEN1KMT2A | |
| SCHEMBL964858 | 0.91 | MEN1 (0.40) | KDM4ECNR2CNR1MEN1KMT2A | |
| SCHEMBL17007605 | 0.79 | CNR1 (0.40) | CNR2CNR1KMT2AALDH1A1LMNA | |
| SCHEMBL965707 | 0.79 | CNR1 (0.43) | KDM4ECNR2CNR1KMT2AALDH1A1 | |
| SCHEMBL17007604 | 0.79 | CNR1 (0.40) | CNR2CNR1KMT2AALDH1A1LMNA | |
| SCHEMBL965709 | 0.79 | CNR1 (0.43) | KDM4ECNR2CNR1KMT2AALDH1A1 | |
| SCHEMBL964659 | 0.76 | CNR2 (0.53) | CNR2CNR1LMNAGAA | |
| SCHEMBL964658 | 0.76 | CNR2 (0.53) | CNR2CNR1LMNAGAA | |
| SCHEMBL961083 | 0.75 | HSD11B1 (0.43) | CNR2CNR1MEN1KMT2AALDH1A1 | |
| SCHEMBL961081 | 0.75 | HSD11B1 (0.43) | CNR2CNR1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | ABBVIE INC. | 2008-03-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | OPRL1, OPRK1, OPRD1 | KDM4E 3198/4885CNR2 5/4885CNR1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.